Genetic screening could help men with prostate cancer find better treatments — and alert family members to their own cancer risk
July 6, 2016
| By Sabrina Richards / Fred Hutch News Service
A new study shows men with metastatic prostate cancer are five times likelier to harbor inherited mutations in BRCA1/2 and other DNA-repair genes than the general population, irrespective of age or family history of prostate cancer.
How a single alteration in fundamental cellular machinery drives blood diseases and cancers
May 11, 2015
| By Rachel Tompa / Fred Hutch News Service
Researchers have now uncovered how a single mutation can trigger myelodysplastic syndrome, or MDS, a disorder akin to leukemia in which the bone marrow overproduces some blood cell precursors but can’t convert them to healthy blood cells.
Tapscott, Snider and global research team further understanding of key genetic mutation, reveal possible drug targets
Aug. 23, 2010
| By Kristen Woodward
An international team of researchers that includes investigators from the Fred Hutchinson Cancer Research Center made a critical advance in determining the cause of a common form of muscular dystrophy known as facioscapulohumeral dystrophy.
PHS findings on BRCA mutations underscore importance of genetic testing in younger patients
April 12, 2010
| By Kristen Woodward
Fred Hutchinson Cancer Research Center Public Health Sciences Division’s Dr. Kathi Malone and colleagues found that women with breast cancer before age 55 who carry an inherited mutation in the breast cancer susceptibility genes BRCA1 or BRCA2 are four times more likely to develop cancer in the breast opposite, or contralateral, to their initial tumor as compared to breast cancer patients without these genetic defects.
Mouth-cell test holds promise for weighing lung cancer risk
Feb. 1, 2010
Dr. Jason Chien of the Fred Hutchinson Cancer Research Center's Clinical Research Division recently received a one-year, $75,000 grant from the Department of Defense Lung Cancer Research Program to study mouth cells as a possible biomarker for lung cancer.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.